^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

FRAME-001

i
Other names: FRAME-001
Associations
Company:
CureVac
Drug class:
Immunostimulant
Related drugs:
Associations
over2years
Development of whole Framome personalized cancer vaccines (CIMT 2022)
Mouse immunogenicity studies with synthetic long peptides showed that Frame neoantigens are immunogenic and induce both CD8+ and CD4+ T cell responses. We have designed and received authorities approval for the first clinical trial with personalized FRAME-001 peptide cancer vaccine for patients with advanced non-small cell lung cancer with unsatisfactory response to the immune checkpoint inhibition.
IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
FRAME-001
over3years
FRAME-001 Personalized Vaccine in NSCLC (clinicaltrials.gov)
P2, N=15, Not yet recruiting, Frame Pharmaceuticals B.V.
New P2 trial
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • FRAME-001